Cross-Species Regulatory Network Analysis Identifies a Synergistic Interaction between FOXM1 and CENPF that Drives Prostate Cancer Malignancy

Cancer Cell

Volumn 25, Issue 5, 2014, Pages 638-651

  Aytes, Alvaro ^a,b   Mitrofanova, Antonina ^a   Lefebvre, Celine ^a,h   Alvarez, Mariano J ^a   Castillo Martin, Mireia ^c   Zheng, Tian ^a,d   Eastham, James A ^e   Gopalan, Anuradha ^e   Pienta, Kenneth J ^f,g   Shen, Michael M ^a   Califano, Andrea ^a   Abate Shen, Cory ^a  

^a NewYork Presbyterian Hospital   (United States)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; DASATINIB; IMATINIB; RAPAMYCIN; SORAFENIB;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CENPF GENE; FOXM1 GENE; GENE; GENE EXPRESSION REGULATION; GENE INTERACTION; GENE REGULATORY NETWORK; GENETIC ASSOCIATION; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TRANSCRIPTION REGULATION;

ALGORITHMS; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMOSOMAL PROTEINS, NON-HISTONE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENE SILENCING; HUMANS; MALE; MICE; MICROFILAMENT PROTEINS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; PROGNOSIS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84900328733     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.03.017     Document Type: Article

References (40)

1. Akavia U.D., Litvin O., Kim J., Sanchez-Garcia F., Kotliar D., Causton H.C., Pochanard P., Mozes E., Garraway L.A., Pe'er D. An integrated approach to uncover drivers of cancer. Cell 2010, 143:1005-1017.
2. Alvarez-Fernandez M., Medema R.H. Novel functions of FoxM1: from molecular mechanisms to cancer therapy. Front. Oncol. 2013, 3:30.
3. Aytes A., Mitrofanova A., Kinkade C.W., Lefebvre C., Lei M., Phelan V., LeKaye H.C., Koutcher J.A., Cardiff R.D., Califano A., et al. ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer. Proc. Natl. Acad. Sci. USA 2013, 110:E3506-E3515.
4. Baca S.C., Prandi D., Lawrence M.S., Mosquera J.M., Romanel A., Drier Y., Park K., Kitabayashi N., MacDonald T.Y., Ghandi M., et al. Punctuated evolution of prostate cancer genomes. Cell 2013, 153:666-677.
5. Basso K., Margolin A.A., Stolovitzky G., Klein U., Dalla-Favera R., Califano A. Reverse engineering of regulatory networks in human Bcells. Nat. Genet. 2005, 37:382-390.
6. Bomont P., Maddox P., Shah J.V., Desai A.B., Cleveland D.W. Unstable microtubule capture at kinetochores depleted of the centromere-associated protein CENP-F. EMBO J. 2005, 24:3927-3939.
7. Cai Y., Balli D., Ustiyan V., Fulford L.A., Hiller A., Misetic V., Zhang Y., Paluch A.M., Waltz S.E., Kasper S., Kalin T.V. Foxm1 expression in prostate epithelial cells is essential for prostate carcinogenesis. J.Biol. Chem. 2013, 288:22527-22541.
8. Carro M.S., Lim W.K., Alvarez M.J., Bollo R.J., Zhao X., Snyder E.Y., Sulman E.P., Anne S.L., Doetsch F., Colman H., et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010, 463:318-325.
9. Cooperberg M.R., Broering J.M., Kantoff P.W., Carroll P.R. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J.Urol. 2007, 178:S14-S19.
10. Donovan M.J., Hamann S., Clayton M., Khan F.M., Sapir M., Bayer-Zubek V., Fernandez G., Mesa-Tejada R., Teverovskiy M., Reuter V.E., et al. Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy. J.Clin. Oncol. 2008, 26:3923-3929.
11. Faith J.J., Hayete B., Thaden J.T., Mogno I., Wierzbowski J., Cottarel G., Kasif S., Collins J.J., Gardner T.S. Large-scale mapping and validation of Escherichia coli transcriptional regulation from a compendium of expression profiles. PLoS Biol. 2007, 5:e8.
12. Feng J., Huang H., Yen T.J. CENP-F is a novel microtubule-binding protein that is essential for kinetochore attachments and affects the duration of the mitotic checkpoint delay. Chromosoma 2006, 115:320-329.
13. Glinsky G.V., Glinskii A.B., Stephenson A.J., Hoffman R.M., Gerald W.L. Gene expression profiling predicts clinical outcome of prostate cancer. J.Clin. Invest. 2004, 113:913-923.
14. Halasi M., Gartel A.L. FOX(M1) news-it is cancer. Mol. Cancer Ther. 2013, 12:245-254.
15. Halasi M., Gartel A.L. Targeting FOXM1 in cancer. Biochem. Pharmacol. 2013, 85:644-652.
16. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
17. Holt S.V., Vergnolle M.A., Hussein D., Wozniak M.J., Allan V.J., Taylor S.S. Silencing Cenp-F weakens centromeric cohesion, prevents chromosome alignment and activates the spindle checkpoint. J.Cell Sci. 2005, 118:4889-4900.
18. Irshad S., Abate-Shen C. Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic. Cancer Metastasis Rev. 2013, 32:109-122.
19. Ittmann M., Huang J., Radaelli E., Martin P., Signoretti S., Sullivan R., Simons B.W., Ward J.M., Robinson B.D., Chu G.C., et al. Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res. 2013, 73:2718-2736.
20. Kalin T.V., Wang I.C., Ackerson T.J., Major M.L., Detrisac C.J., Kalinichenko V.V., Lyubimov A., Costa R.H. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res. 2006, 66:1712-1720.
21. Kalin T.V., Ustiyan V., Kalinichenko V.V. Multiple faces of FoxM1 transcription factor: lessons from transgenic mouse models. Cell Cycle 2011, 10:396-405.
22. Koo C.Y., Muir K.W., Lam E.W. FOXM1: From cancer initiation to progression and treatment. Biochim. Biophys. Acta 2012, 1819:28-37.
23. Lefebvre C., Rajbhandari P., Alvarez M.J., Bandaru P., Lim W.K., Sato M., Wang K., Sumazin P., Kustagi M., Bisikirska B.C., et al. A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers. Mol. Syst. Biol. 2010, 6:377.
24. Lefebvre C., Rieckhof G., Califano A. Reverse-engineering human regulatory networks. Wiley Interdiscip. Rev. Syst Biol. Med. 2012, 4:311-325.
25. Ma L., Zhao X., Zhu X. Mitosin/CENP-F in mitosis, transcriptional control, and differentiation. J.Biomed. Sci. 2006, 13:205-213.
26. Margolin A.A., Nemenman I., Basso K., Wiggins C., Stolovitzky G., Dalla Favera R., Califano A. ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinformatics 2006, 7(Suppl 1):S7.
27. Margolin A.A., Wang K., Lim W.K., Kustagi M., Nemenman I., Califano A. Reverse engineering cellular networks. Nat. Protoc. 2006, 1:662-671.
28. Pan J., Yeung S.C. Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors. Cancer Res. 2005, 65:9109-9112.
29. Radhakrishnan S.K., Bhat U.G., Hughes D.E., Wang I.C., Costa R.H., Gartel A.L. Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res. 2006, 66:9731-9735.
30. Ryan C.J., Tindall D.J. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J.Clin. Oncol. 2011, 29:3651-3658.
31. Sboner A., Demichelis F., Calza S., Pawitan Y., Setlur S.R., Hoshida Y., Perner S., Adami H.O., Fall K., Mucci L.A., et al. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med. Genomics 2010, 3:8.
32. Scher H.I., Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J.Clin. Oncol. 2005, 23:8253-8261.
33. Schoenborn J.R., Nelson P., Fang M. Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification. Clin. Cancer Res. 2013, 19:4058-4066.
34. Shah R.B., Mehra R., Chinnaiyan A.M., Shen R., Ghosh D., Zhou M., Macvicar G.R., Varambally S., Harwood J., Bismar T.A., et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 2004, 64:9209-9216.
35. Shen M.M., Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010, 24:1967-2000.
36. Stanbrough M., Bubley G.J., Ross K., Golub T.R., Rubin M.A., Penning T.M., Febbo P.G., Balk S.P. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006, 66:2815-2825.
37. Taylor B.S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B.S., Arora V.K., Kaushik P., Cerami E., Reva B., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22.
38. Varis A., Salmela A.L., Kallio M.J. Cenp-F (mitosin) is more than amitotic marker. Chromosoma 2006, 115:288-295.
39. Zhang N., Wei P., Gong A., Chiu W.T., Lee H.T., Colman H., Huang H., Xue J., Liu M., Wang Y., et al. FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell 2011, 20:427-442.
40. Zhang Q.C., Petrey D., Deng L., Qiang L., Shi Y., Thu C.A., Bisikirska B., Lefebvre C., Accili D., Hunter T., et al. Structure-based prediction of protein-protein interactions on a genome-wide scale. Nature 2012, 490:556-560.